Chimerix's (CMRX, -3.3%) CMX001 preemptive therapy for adenovirus (AdV) infection failed to achieve statistical significance in a Phase II trial of recipients of blood or bone marrow from donors.
However, Chimerix says that encouraging results from the first proof-of-concept study for adenovirus infection support the continued clinical development of CMX001.
AdV causes respiratory infections such as the common cold in healthy individuals. In patients with weakened immune systems, such as those who have recently received bone marrow or organ transplants, AdV infections have a high mortality rate. (PR)